Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Chimeric Therapeutics (CHM AU)
Watchlist
9
Analysis
Health Care
•
Australia
Chimeric Therapeutics Limited operates as a biotechnology company. The Company develops CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. Chimeric Therapeutics serves customers worldwide.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Chimeric Therapeutics
•
09 Sep 2022 08:00
•
Issuer-paid
Chimeric Therapeutics Limited - Assembling a World-Class Team, Partners and Assets
Chimeric Therapeutics Limited Assembling a world-class team, partners and assets Chimeric Therapeutics Limited (ASX:CHM) is a...
Research as a Service (RaaS)
Follow
563 Views
Share
bullish
•
Chimeric Therapeutics
•
03 Mar 2022 08:00
•
Issuer-paid
Chimeric Therapeutics Ltd - Entitlement Offer to Raise up to $18.1M
Chimeric Therapeutics Ltd Entitlement offer to raise up to $18.1M Chimeric Therapeutics (ASX:CHM) is a clinical-stage cell therapy company...
Research as a Service (RaaS)
Follow
1.1k Views
Share
bullish
•
Chimeric Therapeutics
•
09 Feb 2022 08:00
•
Issuer-paid
Chimeric Therapeutics Ltd: Hitting Milestones and Pipeline Flowing
Chimeric Therapeutics Ltd Hitting milestones and pipeline flowing Chimeric Therapeutics (ASX:CHM) is a clinical-stage cell therapy company...
Research as a Service (RaaS)
Follow
1.1k Views
Share
bullish
•
Chimeric Therapeutics
•
17 Dec 2021 08:00
•
Issuer-paid
Chimeric Therapeutics Ltd: Adding to the Pipeline with a Clinical Platform Technology
Chimeric Therapeutics Ltd Adding to the pipeline with a clinical platform technology Chimeric Therapeutics (ASX:CHM) is a clinical-stage cell...
Research as a Service (RaaS)
Follow
1.4k Views
Share
bullish
•
Chimeric Therapeutics
•
06 Dec 2021 16:20
•
Issuer-paid
Chimeric Therapeutics - Acquiring an exciting new NK cell technology
Chimeric has announced that it has entered into an exclusive option agreement to license the clinically validated, off the shelf, robust, enhanced...
Edison Investment Research
Follow
1.3k Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.69.1
x